Beam Therapeutics Inc
$ 29.49
-3.22%
10 Jun - close price
- Market Cap 3,081,233,000 USD
- Current Price $ 29.49
- High / Low $ 31.50 / 29.43
- Stock P/E N/A
- Book Value 11.71
- EPS -0.49
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.06 %
- 52 Week High 36.44
- 52 Week Low 15.60
About
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$51.07
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.91 | 2.33 | -1.1 | -1 | -1.24 | -1.09 | -1.17 | -1.11 | -1.21 | 1.73 | -1.22 | -1.08 |
| Estimated EPS | -1.01 | -1.01 | -1.01 | -1.09 | -1.17 | -1.2158 | -1.18 | -1.12 | -1.39 | -1.01 | -1.27 | -1.38 |
| Surprise | 0.1 | 3.34 | -0.09 | 0.09 | -0.07 | 0.1258 | 0.01 | 0.01 | 0.18 | 2.74 | 0.05 | 0.3 |
| Surprise Percentage | 9.901% | 330.6931% | -8.9109% | 8.2569% | -5.9829% | 10.3471% | 0.8475% | 0.8929% | 12.9496% | 271.2871% | 3.937% | 21.7391% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BEAM
2026-06-11 01:08:49
Amova Asset Management Americas Inc. has reduced its stake in Beam Therapeutics Inc. ($BEAM) by 8.7% in the fourth quarter, selling 421,438 shares, though it still holds 4.35% of the company. Company insiders also sold shares, totaling approximately $1.9 million over the past three months, primarily for tax withholding on equity awards. Despite these sales, Beam Therapeutics reported strong quarterly revenue growth and earnings per share that exceeded analyst expectations, leading to a consensus "Moderate Buy" rating from analysts with an average price target of $46.83.
2026-06-10 15:39:07
Beam Therapeutics (BEAM) saw a 5.2% stock increase following positive clinical trial data for its gene-editing candidate BEAM-302. The data suggests potential for an accelerated FDA review pathway for treating alpha-1 antitrypsin deficiency, strengthening Beam's genetic medicine pipeline. While this offers a near-term catalyst and extends the company's financial runway into mid-2029, investors are cautioned about the reliance on early-stage data and the need for successful pivotal trials to validate Beam's base editing platform.
2026-06-10 01:08:49
Geode Capital Management LLC reduced its stake in Beam Therapeutics Inc. by 1.6% in the fourth quarter, selling 39,035 shares but still holding 2.35 million shares valued at $65.2 million. Despite the sale, institutional investors own 99.68% of the company's stock. Beam Therapeutics reported a smaller-than-expected quarterly loss and significantly higher revenue, leading analysts to maintain a "Moderate Buy" rating with an average target price of $46.83.
2026-06-08 19:39:42
Beam Therapeutics (Nasdaq: BEAM) shareholders approved the election of three Class III directors, John Evans, John Maraganore, Ph.D., and Christi Shaw, at their 2026 annual meeting. Shareholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and gave advisory approval to the compensation of the company's named executive officers. All proposals received strong shareholder support.
2026-06-07 18:09:57
Beam Therapeutics (BEAM) is regaining investor attention after new clinical data for its BEAM-302 program showed sustained protective protein levels, potentially supporting an accelerated FDA review. Despite recent share price volatility, the company's "molecular pencil" base editing technology offers precision genetic medicine. While a narrative fair value suggests the stock is significantly undervalued at $150 compared to its current price of $29.40, risks remain regarding future data outcomes and regulatory decisions.
2026-06-06 12:10:33
Beam Therapeutics director Guindo Chirfi was granted 19,676 stock options as equity compensation, with an exercise price of $29.55 per share and an expiration date of June 3, 2036. The options will vest either on the first anniversary of the grant date or immediately before the next annual stockholders' meeting, provided Chirfi remains on the board. This transaction is categorized as routine director compensation, not an open-market purchase or sale.
